Cargando…
Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat
AIM: Chemotherapy with doxorubicin is limited by cardiotoxicity. Free radical generation and mitochondrial dysfunction are thought to contribute to doxorubicin-induced cardiac failure. In this study we wanted to investigate if opening of mitochondrial K(ATP)-channels by diazoxide is protective again...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045949/ https://www.ncbi.nlm.nih.gov/pubmed/24887454 http://dx.doi.org/10.1186/2050-6511-15-28 |
_version_ | 1782319417693044736 |
---|---|
author | Hole, Lisa Drange Larsen, Terje Hjalmar Fossan, Kjell Ove Limé, Fredrik Schjøtt, Jan |
author_facet | Hole, Lisa Drange Larsen, Terje Hjalmar Fossan, Kjell Ove Limé, Fredrik Schjøtt, Jan |
author_sort | Hole, Lisa Drange |
collection | PubMed |
description | AIM: Chemotherapy with doxorubicin is limited by cardiotoxicity. Free radical generation and mitochondrial dysfunction are thought to contribute to doxorubicin-induced cardiac failure. In this study we wanted to investigate if opening of mitochondrial K(ATP)-channels by diazoxide is protective against doxorubicin cardiotoxicity, and if 5-hydroxydecanoate (5-HD), a selective mitochondrial K(ATP)-channel antagonist, abolished any protection by this intervention. METHODS: Wistar rats were divided into 7 groups (n = 6) and followed for 10 days with 5 intervention groups including the following treatments: (1) Diazoxide and doxorubicin, (2) diazoxide and 5-hydroxydecanoate (5-HD), (3) 5-HD and doxorubicin, (4) diazoxide and saline and (5) 5-HD and saline. On day 1, 3, 5 and 7 the animals received intraperitoneal (i.p.) injections with 10 mg/kg diazoxide and/or 40 mg/kg 5-HD, 30 minutes before i.p. injections with 3.0 mg/kg doxorubicin. One control group received only saline injections and the other control group received saline 30 minutes prior to 3.0 mg/kg doxorubicin. On day 10 the hearts were excised and Langendorff-perfused. Cardiac function was assessed by an intraventricular balloon and biochemical effects by release of hydrogen peroxide (H(2)O(2)) and troponin-T (TnT) in effluate from the isolated hearts, and by myocardial content of doxorubicin. RESULTS: Doxorubicin treatment produced a significant loss in left ventricular developed pressure (LVDP) (p < 0.05) and an increase in both H(2)O(2) and TnT release in effluate (p < 0.05). Diazoxide significantly attenuated the decrease in LVDP (p < 0.05) and abolished the increased release of H(2)O(2) and TnT (p < 0.05). 5-HD abolished the effects of pretreatment with diazoxide, and these effects were not associated with reduced myocardial accumulation of doxorubicin. CONCLUSIONS: Pretreatment with diazoxide attenuates doxorubicin-induced cardiac dysfunction in the rat, measured by physiological indices and TnT and H(2)O(2) in effluate from isolated hearts. The effect could be mediated by opening of mitochondrial K(ATP)-channels, reduced doxorubicin-associated free radical generation and decreased cardiomyocyte damage. Diazoxide represents a promising protective intervention against doxorubicin-induced acute cardiotoxicity. |
format | Online Article Text |
id | pubmed-4045949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40459492014-06-06 Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat Hole, Lisa Drange Larsen, Terje Hjalmar Fossan, Kjell Ove Limé, Fredrik Schjøtt, Jan BMC Pharmacol Toxicol Research Article AIM: Chemotherapy with doxorubicin is limited by cardiotoxicity. Free radical generation and mitochondrial dysfunction are thought to contribute to doxorubicin-induced cardiac failure. In this study we wanted to investigate if opening of mitochondrial K(ATP)-channels by diazoxide is protective against doxorubicin cardiotoxicity, and if 5-hydroxydecanoate (5-HD), a selective mitochondrial K(ATP)-channel antagonist, abolished any protection by this intervention. METHODS: Wistar rats were divided into 7 groups (n = 6) and followed for 10 days with 5 intervention groups including the following treatments: (1) Diazoxide and doxorubicin, (2) diazoxide and 5-hydroxydecanoate (5-HD), (3) 5-HD and doxorubicin, (4) diazoxide and saline and (5) 5-HD and saline. On day 1, 3, 5 and 7 the animals received intraperitoneal (i.p.) injections with 10 mg/kg diazoxide and/or 40 mg/kg 5-HD, 30 minutes before i.p. injections with 3.0 mg/kg doxorubicin. One control group received only saline injections and the other control group received saline 30 minutes prior to 3.0 mg/kg doxorubicin. On day 10 the hearts were excised and Langendorff-perfused. Cardiac function was assessed by an intraventricular balloon and biochemical effects by release of hydrogen peroxide (H(2)O(2)) and troponin-T (TnT) in effluate from the isolated hearts, and by myocardial content of doxorubicin. RESULTS: Doxorubicin treatment produced a significant loss in left ventricular developed pressure (LVDP) (p < 0.05) and an increase in both H(2)O(2) and TnT release in effluate (p < 0.05). Diazoxide significantly attenuated the decrease in LVDP (p < 0.05) and abolished the increased release of H(2)O(2) and TnT (p < 0.05). 5-HD abolished the effects of pretreatment with diazoxide, and these effects were not associated with reduced myocardial accumulation of doxorubicin. CONCLUSIONS: Pretreatment with diazoxide attenuates doxorubicin-induced cardiac dysfunction in the rat, measured by physiological indices and TnT and H(2)O(2) in effluate from isolated hearts. The effect could be mediated by opening of mitochondrial K(ATP)-channels, reduced doxorubicin-associated free radical generation and decreased cardiomyocyte damage. Diazoxide represents a promising protective intervention against doxorubicin-induced acute cardiotoxicity. BioMed Central 2014-05-27 /pmc/articles/PMC4045949/ /pubmed/24887454 http://dx.doi.org/10.1186/2050-6511-15-28 Text en Copyright © 2014 Hole et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Hole, Lisa Drange Larsen, Terje Hjalmar Fossan, Kjell Ove Limé, Fredrik Schjøtt, Jan Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat |
title | Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat |
title_full | Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat |
title_fullStr | Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat |
title_full_unstemmed | Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat |
title_short | Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat |
title_sort | diazoxide protects against doxorubicin-induced cardiotoxicity in the rat |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045949/ https://www.ncbi.nlm.nih.gov/pubmed/24887454 http://dx.doi.org/10.1186/2050-6511-15-28 |
work_keys_str_mv | AT holelisadrange diazoxideprotectsagainstdoxorubicininducedcardiotoxicityintherat AT larsenterjehjalmar diazoxideprotectsagainstdoxorubicininducedcardiotoxicityintherat AT fossankjellove diazoxideprotectsagainstdoxorubicininducedcardiotoxicityintherat AT limefredrik diazoxideprotectsagainstdoxorubicininducedcardiotoxicityintherat AT schjøttjan diazoxideprotectsagainstdoxorubicininducedcardiotoxicityintherat |